

Zensar Tech: AI Pivot; Weak Demand Clouds Near-term Growth

BUY

April 26, 2026 | CMP: INR 536 | Target Price: INR 650

Expected Share Price Return: 21.0% | Dividend Yield: 2.5% | Potential Upside: 22.5%

Sector View: Neutral

Change in Estimates	✓
Target Price Change	✓
Recommendation	✗

Company Info	
BB Code	ZENT IN EQUITY
Face Value (INR)	2.0
52 W High/Low (INR)	895/511
Mkt Cap (Bn)	INR 122.0/ \$1.3
Shares o/s (Mn)	229.6
3M Avg. Daily Volume	538,017


Change in Estimates						
	FY27E			FY28E		
INR Bn	New	Old	Dev. (%)	New	Old	Dev. (%)
Revenues	63.9	63.3	0.9	69.1	69.8	(0.9)
EBIT	9.4	9.8	(4.1)	10.5	11.1	(5.2)
EBITM %	14.7	15.4	(76) bps	15.2	15.9	(68) bps
EPS	37.9	39.4	(3.8)	42.2	44.1	(4.2)

Actual vs CIE Estimates				
INR Bn	Q4FY26A	CIE Est.	Dev. %	
Revenue	14.5	14.4	0.8	
EBIT	2.1	2.2	(3.3)	
EBITM %	14.7	15.3	(62) bps	
PAT	2.1	2.1	0.3	

Key Financials					
INR Bn	FY25	FY26	FY27E	FY28E	FY29E
Revenue	52.8	56.9	63.9	69.1	72.9
YoY (%)	7.7	7.7	12.3	8.3	5.5
EBIT	7.1	8.2	9.4	10.5	11.5
EBITM %	13.5	14.5	14.7	15.2	15.8
Adj PAT	6.5	7.7	8.7	9.7	10.7
FDEPS	28.4	33.7	37.9	42.2	46.5
ROE %	16.0	16.4	16.8	17.0	17.0
ROCE %	17.1	16.4	17.3	18.0	18.2
PE(x)	25.5	15.9	14.2	12.7	11.5

Shareholding Pattern (%)				
	Mar-26	Dec-25	Sept-25	
Promoters	49.01	49.01	49.03	
FIIIs	10.51	11.80	13.30	
DIIIs	23.66	23.12	22.24	
Public	16.48	15.71	15.43	

Relative Performance (%)				
YTD	3Y	2Y	1Y	
BSE IT	3.6	(19.3)	(20.6)	
ZENT	100.3	(7.8)	(23.8)	


Dhanshree Jadhav

Email: dhanshree.jadhav@choiceindia.com

Ph: +91 22 6707 9535

Shreya Mehra

Email: shreya.mehra@choiceindia.com

Ph: +91 22 6707 9901

Q4FY26 Technology Result Preview
Steady Performance amid Weak Demand & Margin Headwinds

ZENT delivered a mixed Q4FY26, with underlying demand weakening. A key positive was mega deal win of USD 401.8 Mn (+123% QoQ), signalling robust pipeline traction and improving client confidence. While management expects near-term margin pressure in H1FY27 due to large deal transition costs, it has maintained its full-year margin guidance of 14–16%, indicating confidence in underlying operational levers. We remain structurally constructive on the long-term story, as ZENT continues to transition toward an AI-native enterprise, embedding AI across offerings and scaling capabilities such as Quality Intelligence and Agentic AI to expand its addressable market. However, we expect near-term headwinds to persist, driven by continued softness in TMT and HLS, client exits due to consolidation, and margin pressure from upfront investments and transition costs. **We expect Revenue/EBIT/PAT CAGR of 8.7%/11.8%/11.4% over FY26–29E. Accordingly, while the long-term thesis remains intact, we moderate our near-term expectations and revise our target price to INR 650 (implied PE 15x) to reflect these transitory challenges. Maintain 'BUY'.**

Muted Revenue Growth; Strong Deal Pipeline and Stable Profitability

- In Q4FY26, ZENT posted revenue of USD 158.4 Mn, down 1.3% QoQ (vs CIE estimate of -1.9% QoQ). CC growth came in at -1.9% QoQ. In INR terms, revenue stood at INR 14,504 Mn, up 1.4% QoQ (vs CIE estimate of +0.6% QoQ). For the full year, revenue came in at USD 643.7 Mn, up 3.1% YoY, whereas in INR terms, it stood at INR 56,874, up 7.7% YoY.
- EBIT margin came in at 14.7% (vs CIE estimate of 15.3%) for Q4FY26, down 130 bps QoQ and, for FY26, it stood at 14.5%, up 100 bps YoY.
- PAT for the quarter stood at INR 2,106 Mn, up 5.4% QoQ (vs CIE estimate of +5.1% QoQ), whereas, for FY26, PAT stood at INR 7,746 Mn, up 19.2% YoY.

Robust Order Book; TMT Vertical Pressures Persist

ZENT's reported record deal momentum with an all-time high quarterly order book of USD 401.8 Mn, up 123% QoQ. Even excluding the mega deal, order bookings remained strong at approximately USD 206 Mn for the quarter. Vertical-wise, BFS (+1.2%) was the top performer; whereas HLS (-6.6%), TMT (-3.8%) and Manufacturing & Consumer Services (-3.9%) de-grew sequentially due to continuous pressure led by significant cost-cutting and insourcing. HLS is expected to remain flat in FY27 as the company 'consolidated out' of a couple of accounts. However, strong deal wins imply stabilisation in core verticals, with early signs of recovery, led by cost optimisation and transformation-led demand.

Margins Soft Near-term; Structural Stability Intact

EBIT margin came in at 14.7% for Q4FY26, down 130 bps QoQ and for FY26, it stood at 14.5%, up 97 bps YoY. The margin contraction was a sum of factors such as lower volumes due to fewer working days, reversal of leave utilisation benefits from Q3 increased SG&A costs, which were partially offset by a 1.2% positive forex impact. Margin pressure is anticipated to persist in the H1 of FY27 majorly due to upfront investments and transition costs for the mega deal. The management maintained their long-term guidance of mid-teens (14% to 16%) for the full year.

ZENT Ltd.	Q4FY26	Q3FY26	QoQ (%)	Q4FY25	YoY (%)
Revenues (USD Mn)	158	161	(1.3)	157	1.0
Revenues (INR Mn)	14,504	14,307	1.4	13,589	6.7
EBIT (INR Mn)	2,130	2,297	(7.3)	1,887	12.9
EBIT Margin (%)	14.7	16.1	(137) bps	13.9	80 bps
Other income	650	631	3.0	460	41.3
Interest	25	23	8.7	49	(49.0)
PBT	2,760	2,651	4.1	2,298	20.1
Tax	653	652	0.2	534	22.3
Adj. PAT (INR Mn)	2,107	1,998	5.5	1,764	19.4
FDEPS (INR)	9.2	8.7	5.5	7.7	19.1

Source: ZENT, Choice Institutional Equities

Management Call - Highlights

A major highlight was a strategic mega deal with a gross value of USD 210 Mn signed in February this year. This deal is expected to begin contributing revenue with a full-fledged ramp-up anticipated from Q3FY27 onwards. However, the deal transition costs will start from Q1FY27.

The management has reimagined its service lines to be AI-native, launching offerings such as Quality Intelligence for intent-based testing, Agentic Foundry for BFSI workflows and solutions, such as Context Intelligence, FinOps for AI, and ZenseAI.Guidewire.

While overall growth was modest, specific service lines showed robust YoY performance in reported currency: 1. Cloud Infrastructure and Security Services, up 13%, Data Engineering and Analytics, up 8%, Products and Platforms (including CMO services), up 6% and Enterprise Application Services, up 1.2%.

The Board approved a final dividend of 12.6 per share (630% of face value), bringing the total dividend for the year to 750% of face value.


- **A major highlight was a strategic mega deal with a gross value of USD 210 Mn signed in February this year. This deal is expected to begin contributing revenue with a full-fledged ramp-up anticipated from Q3FY27 onwards. However, the deal transition costs will start from Q1FY27.**
- Management is "all in on AI," having upskilled 85% of its workforce in AI technologies. The company has reimagined all service lines to be AI-native, launching new offerings, such as Quality Intelligence (QI).
- **The company reported its highest-ever customer satisfaction (CSAT) score and maintained industry-leading low voluntary attrition of 9.8%. To further tap into high-quality talent, it recently opened a new delivery center in Belgrade, Serbia.**
- While conversion cycles remain slightly elongated due to macro uncertainty, strong deal momentum provides good visibility for FY27, with revenue growth expected to be driven by gradual ramp-up of these large wins.
- **The management has reimagined its service lines to be AI-native, launching offerings such as Quality Intelligence for intent-based testing, Agentic Foundry for BFSI workflows and solutions, such as Context Intelligence, FinOps for AI, and ZenseAI.Guidewire.**
- Zensar is using AI to expand its addressable market beyond the CIO's office, targeting adjacent areas such as CMO, HR and Finance.
- The company is driving internal AI adoption across functions, with AI-enabled recruitment and end-to-end employee lifecycle management in HR, alongside deployment in finance and legal for AR/AP, FP&A and faster contract processing through in-house AI agents.
- **While overall growth was modest, specific service lines showed robust YoY performance in reported currency: 1. Cloud Infrastructure and Security Services, up 13%, Data Engineering and Analytics, up 8%, Products and Platforms (including CMO services), up 6% and Enterprise Application Services, up 1.2%.**
- Employee headcount stood at 10,779 as of Q4FY26, net addition of 968 employees in this quarter.
- Voluntary LTM attrition remains one of the lowest in the industry at 9.8% in Q4FY26 as compared to 9.5% in Q3FY26.
- Net cash and cash equivalents grew 10% YoY to USD 319.5 Mn.
- The Effective Tax Rate (ETR) for the quarter was 23.7%. The management expects the FY27 tax rate to stay within the range of the normal corporate tax rate.
- **The Board approved a final dividend of INR 12.6 per share (630% of face value), bringing the total dividend for the year to 750% of face value.**

Sequential Operating Performance

	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26	Q4FY26
Income Statement								
Revenues (USD Mn)	154	156	157	157	162	163	161	158
Revenues (INR Mn)	12,881	13,080	13,256	13,589	13,850	14,213	14,307	14,504
Gross Profit (INR Mn)	3,054	2,841	3,028	2,967	3,157	3,003	4,832	4,750
Gross Margin (%)	23.7	21.7	22.8	21.8	22.8	21.1	33.8	32.7
EBITDA (INR Mn)	1,962	2,010	2,070	2,125	2,106	2,200	2,500	2,357
EBITDA Margin (%)	15.2	15.4	15.6	15.6	15.2	15.5	17.5	16.3
PAT (INR Mn)	1,579	1,557	1,598	1,764	1,820	1,822	1,998	2,107
FDEPS (INR)	6.9	6.8	6.9	7.6	7.9	7.9	8.6	9.2
Operating Metrics								
Revenue - Geography (%)								
North America	68.7	67.6	67.3	67.4	68.3	66.6	65.5	65.3
Europe	19.8	21.1	21.2	21.4	20.5	21.5	22.0	22.1
Africa	11.5	11.3	11.5	11.2	11.2	11.9	12.4	12.7
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Revenue - Segments (%)								
TMT (Telecom-Media-Technology)	24.7	22.4	21.4	21.7	22.3	20.0	18.5	18.1
MCS (Mfg. & Consumer Services)	25.8	26.2	27.7	26.7	25.3	25.2	26.4	25.8
BFS (Banking & Financial Services)	39.7	40.9	40.1	41.0	41.5	43.6	44.0	45.6
Healthcare & Life Sciences	9.8	10.5	10.8	10.6	10.9	11.2	11.1	10.5
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Employee Metrics								
Total Headcount	10,396	10,240	10,517	10,702	10,620	10,550	10,732	10,779
Attrition Rate LTM (%)	10.6	10.1	10.0	9.9	9.8	9.8	9.5	9.8
Trainees(%)	83.9	82.8	82.9	84.6	84.3	84.8	83.5	84.3
Revenue Split (%)								
Onsite	51.4	49.7	49.5	49.0	47.4	45.8	45.5	46.2
Offshore	48.6	50.3	50.5	51.0	52.6	54.2	54.5	53.8
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0


Source: ZENT, Choice Institutional Equities

Revenue declined 1.3% QoQ




Source: ZENT, Choice Institutional Equities

Revenue expected to expand at 5.7% CAGR over FY26–29E




Source: ZENT, Choice Institutional Equities

EBITM declined by 120 bps in Q4FY26




Source: ZENT, Choice Institutional Equities

EBIT anticipated to expand at 11.8% CAGR over FY26–29E




Source: ZENT, Choice Institutional Equities

PATM increased to 14.5% owing to absence of Labour Code cost




Source: ZENT, Choice Institutional Equities

PAT projected to expand at 11.4% CAGR over FY26–29E




Source: ZENT, Choice Institutional Equities

Attrition rate increased to 9.8%




Source: ZENT, Choice Institutional Equities

BFS vertical revenue share continues to expand




Source: ZENT, Choice Institutional Equities

Growth was led by the UK & South Africa markets




Source: ZENT, Choice Institutional Equities

Onsite & offshore mix




Source: ZENT, Choice Institutional Equities

ROE & ROCE trend



Source: ZENT, Choice Institutional Equities

1-year forward PE band



Source: ZENT, Choice Institutional Equities

Income Statement (Consolidated in INR Mn)

Particular	FY25	FY26	FY27E	FY28E	FY29E
Revenue (USD Mn)	624	644	680	720	760
Revenue	52,806	56,874	63,852	69,145	72,950
Gross profit	15,695	18,217	20,762	23,005	24,470
EBITDA	8,168	9,162	10,290	11,458	12,434
Depreciation	1,019	913	920	920	920
EBIT	7,149	8,249	9,370	10,538	11,514
Other income	1,602	2,339	2,265	2,408	2,750
Interest expense	173	121	82	76	71
PAT	6,499	7,746	8,723	9,717	10,715
EPS	28.4	33.7	37.9	42.2	46.5

Ratio Analysis	FY25	FY26	FY27E	FY28E	FY29E
Growth Ratios (%)					
Revenues (USD)	5.4	3.1	5.6	6.0	5.5
Revenues (INR)	7.7	7.7	12.3	8.3	5.5
EBITDA	(6.3)	12.2	12.3	11.3	8.5
EBIT	(3.1)	15.4	13.6	12.5	9.3
Margin Ratios (%)					
EBITDA Margin	15.5	16.1	16.1	16.6	17.0
EBIT Margin	13.5	14.5	14.7	15.2	15.8
Profitability (%)					
ROE	16.0	16.4	16.8	17.0	17.0
ROIC	18.4	18.1	18.8	19.2	19.4
ROCE	17.1	16.4	17.3	18.0	18.2
Financial Leverage					
OCF / Net profit (%)	86.9	125.6	84.6	82.0	85.8
EV/ EBITDA (x)	17.7	10.4	9.1	8.1	7.2
BVPS (x)	179.3	208.3	229.6	252.8	278.1
Free Cash Flow Yield(%)	3.3	7.1	5.3	5.8	6.8

Source: ZENT, Choice Institutional Equities


Balance Sheet (Consolidated in INR Mn)

Particular	FY25	FY26	FY27E	FY28E	FY29E
Tangible fixed assets	914	1,061	1,061	1,061	1,061
Goodwill & intangible assets	9,819	10,508	10,508	10,508	10,508
Investments	7,850	8,763	9,763	10,763	11,763
Cash & Cash equivalents	19,973	25,909	27,551	29,202	31,555
Other non-current assets	-	-	-	-	-
Other current assets	13,173	14,594	15,774	17,371	18,744
Total Assets	51,729	60,835	64,657	68,906	73,631
Shareholder's funds	40,697	47,191	52,013	57,262	62,987
Minority interest	-	-	-	-	-
Borrowings	-	-	-	-	-
Other non-current liabilities	2,210	2,144	2,144	2,144	2,144
Other current liabilities	8,822	11,500	10,500	9,500	8,500
Total Equity & Liabilities	51,729	60,835	64,657	68,906	73,631

Cash Flows (INR Mn)	FY25	FY26	FY27E	FY28E	FY29E
Cash Flows From Operations	5,650	7,708	7,381	7,963	9,191
Cash Flows From Investing	(4,877)	(2,406)	(1,920)	(1,920)	(1,920)
Cash Flows From Financing	(2,645)	(4,010)	(3,819)	(4,392)	(4,919)

DuPont Analysis	FY25	FY26	FY27E	FY28E	FY29E
ROE	16.0%	16.4%	16.8%	17.0%	17.0%
Net Profit Margin	12.3%	13.6%	13.7%	14.1%	14.7%
Asset Turnover	1.0	0.9	1.0	1.0	1.0
Equity Multiplier	1.3	1.3	1.2	1.2	1.2

Historical share price chart: Zensar Technologies Limited



Date	Rating	Target Price
July 01, 2025	BUY	1,130
July 23, 2025	BUY	1,130
November 3, 2025	BUY	1,000
January 25, 2026	BUY	880
March 02, 2026	BUY	900
April 06, 2026	BUY	920
April 26, 2026	BUY	650

Institutional Research Team

Utsav Verma, CFA	Head of Institutional Research	utsav.verma@choiceindia.com	+91 22 6707 9440
Ambrish Shah	Analyst - Power	ambrish.shah@choiceindia.com	+91 22 6707 9251
Ashutosh Murarka	Analyst – Building Materials	ashutosh.murarka@choiceindia.com	+91 22 6707 9521
Bhavik Shah, CFA	Analyst – Metals & Mining	Bhavik.shah@choiceindia.com	+91 22 6707 9521
Deepika Murarka	Analyst – Healthcare	deepika.murarka@choiceindia.com	+91 22 6707 9513
Dhanshree Jadhav	Analyst – Technology	dhanshree.jadhav@choiceindia.com	+91 22 6707 9535
Dhaval Popat	Analyst – Energy	dhaval.popat@choiceindia.com	+91 22 6707 9949
Fenil Brahmhatt	Analyst – Realty & Building Materials	fenil.brahmhatt@choiceindia.com	+91 22 6707 9930
Ishank Gupta	Analyst – NBFCs	ishank.gupta@choiceindia.com	+91 22 6707 9867
Karan Kamdar	Analyst – Consumer Discretionary, Small and Midcaps	karan.kamdar@choiceindia.com	+91 22 6707 9451
Kunal Bajaj	Analyst – Technology	kunal.bajaj@choiceindia.com	+91 22 6707 9901
Maitri Sheth	Analyst – Pharmaceuticals	maitri.sheth@choiceindia.com	+91 22 6707 9511
Putta Ravi Kumar	Analyst – Defence	ravi.putta@choiceindia.com	+91 22 6707 9908
Preeyam Tolia	Analyst – FMCG & Retail	preeyam.tolia@choiceindia.com	+91 22 6707 9987
Aayush Saboo	Sr. Associate– Realty	aayush.saboo@choiceindia.com	+91 22 6707 9930
Avi Jhaveri	Sr. Associate – Technology	avi.jhaveri@choiceindia.com	+91 22 6707 9901
Bharat Kumar Kudikyala	Sr. Associate – Building Materials	bharat.kudikyala@choiceindia.com	+91 22 6707 9521
Samarth Goel	Sr. Associate– Small and Midcaps	samarth.goel@choiceindia.com	+91 22 6707 9451
Subhash Gate	Sr. Associate – Autos	subhash.gate@choiceindia.com	+91 22 6707 9233
Heer Gogri	Associate – Small and Midcaps	heer.gogri@choiceindia.com	+91 22 6707 9433
Heet Chheda	Associate – Autos	heet.chheda@choiceindia.com	+91 22 6707 9233
Rushil Katiyar	Associate – Technology	rushil.katiyar@choiceindia.com	+91 22 6707 9901
Shreya Mehra	Associate – Technology	shreya.mehra@choiceindia.com	+91 22 6707 9535
Stuti Bagadia	Associate – Pharmaceuticals	stuti.bagadia@choiceindia.com	+91 22 6707 9511
Vinay Rawal	Associate – Small and Midcaps	vinay.rawal@choiceindia.com	+91 22 6707 9433

CHOICE RATING DISTRIBUTION & METHODOLOGY

Large Cap*	
BUY	The security is expected to generate upside of 15% or more over the next 12 months
ADD	The security is expected to show upside returns from 5% to less than 15% over the next 12 months
REDUCE	The security is expected to show upside or downside returns by 5% to -5% over the next 12 months
SELL	The security is expected to show downside of 5% or more over the next 12 months
Mid & Small Cap*	
BUY	The security is expected to generate upside of 20% or more over the next 12 months
ADD	The security is expected to show upside returns from 5% to less than 20% over the next 12 months
REDUCE	The security is expected to show upside or downside returns by 5% to -10% over the next 12 months
SELL	The security is expected to show downside of 10% or more over the next 12 months
Other Ratings	
NOT RATED (NR)	The stock has no recommendation from the Analyst
UNDER REVIEW (UR)	The stock is under review by the Analyst and rating may change
Sector View	
POSITIVE (P)	Fundamentals of the sector look attractive over the next 12 months
NEUTRAL (N)	Fundamentals of the sector are expected to be in stasis over the next 12 months
CAUTIOUS (C)	Fundamentals of the sector are expected to be challenging over the next 12 months

*Large Cap: More Than INR 20,000 Cr Market Cap
*Mid & Small Cap: Less Than INR 20,000 Cr Market Cap

Disclaimer & Disclosure

Research Disclaimer and Disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

Choice Equity Broking Private Limited is a registered Research Analyst Entity (Reg. No. INH00000222) CIN. NO.: U65999MH2010PTC198714. Reg. Add.: Sunil Patodia Tower, J B Nagar, Andheri (East), Mumbai 400099. Tel. No. 022-6707 9999 . Compliance Officer-Prashant Salian. Tel. 022-6707 9999-Ext. 896. Email- Compliance@choiceindia.com. Grievance officer-Deepika Singhvi Tel.022-67079999- Ext-834.

Email- ig@choiceindia.com

General Disclaimer:

Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

This report ("Report") is prepared by Choice Equity Broking Private Limited as a Research Entity (hereinafter referred as "CEBPL") in its capacity as a SEBI-registered Research Analyst and is intended solely for informational and educational purposes. This Report is meant exclusively for the recipient and shall not be circulated, reproduced, or distributed, in whole or in part.

This Report does not take into account the specific investment objectives, financial situation, risk profile, or particular needs of any individual or class of investors and does not constitute a personal recommendation or investment advice. Any views, opinions, or recommendations expressed herein are based on publicly available information and internal analysis and are subject to change without notice.

Nothing contained in this Report shall be construed as an offer, solicitation, or inducement to buy, sell, or subscribe to any securities, derivatives, or other financial instruments, nor shall it be considered as investment, legal, accounting, or tax advice. Recipients are advised to conduct their own independent analysis and are encouraged to seek independent professional advice before making any investment or trading decisions.

The information contained in this Report has been compiled from sources believed to be reliable; however, CEBPL does not represent or warrant the accuracy, completeness, or reliability of such information. CEBPL, its directors, employees, or associates shall not be liable for any losses, damages, or expenses arising directly or indirectly from the use of or reliance upon this Report.

Investments in securities are subject to market risks. The price and value of investments and the income from them may fluctuate, and investors may incur losses. Past performance is not indicative of future results. Opinions expressed herein are as of the date of this Report and may differ from views expressed in other research reports due to differences in methodology, assumptions, or time horizons.

Disclaimers in respect of Jurisdiction:

This Report is not intended for distribution to, or use by, any person or entity who is a citizen or resident of, or located in, any jurisdiction where such distribution, publication, or use would be contrary to applicable laws or regulations, or would subject CEBPL to any registration or licensing requirements in such jurisdiction.

No action has been taken or will be taken by CEBPL in any jurisdiction outside India where such action would be required for distribution of this Report. Accordingly, this Report shall not be directly or indirectly distributed, published, or circulated in any such jurisdiction except in compliance with applicable laws and regulations.

Recipients of this Report are required to inform themselves of, and comply with, all applicable legal and regulatory restrictions at their own expense and without any liability to CEBPL. Any dispute arising out of or in connection with this Report shall be subject to the exclusive jurisdiction of the competent courts in Mumbai, India.

Disclosure on Ownership and Material Conflicts of Interest:

- "CEBPL", its Research Analyst(s), their associates and relatives may have any financial interest in the subject company covered in this Research Report.
- "CEBPL", its Research Analyst(s), their associates and relatives may have actual or beneficial ownership of one percent (1%) or more of the securities of the subject company, as on the last day of the month immediately preceding the date of publication of this Research Report.
- "CEBPL", its Research Analyst(s), their associates and relatives may have any other material conflict of interest at the time of publication of this Research Report.

Disclosure on Receipt of Compensation:

- "CEBPL" or its associates may have received compensation from the subject company during the past twelve months.
- "CEBPL" or its associates may have managed or co-managed public offerings of securities for the subject company during the past twelve months.
- "CEBPL" or its associates may have received compensation from the subject company during the past twelve months for investment banking, merchant banking or brokerage services.
- "CEBPL" or its associates may have received compensation from the subject company during the past twelve months for products or services other than investment banking, merchant banking or brokerage services.
- "CEBPL" or its associates have not received any compensation or other benefits from the subject company or any third party in connection with the preparation or publication of this Research Report.
- Research Analyst may have served as an officer, director or employee of the subject company covered in this Research Report.
- "CEBPL" and Research analyst may engage in market-making activity in the securities of the subject company.

Details of Associates of CEBPL and Brief History of Disciplinary action by regulatory authorities are available on our website i.e. [www. https://choiceindia.com/research-listing](http://www.https://choiceindia.com/research-listing)

Copyright:

This research report is confidential and intended solely for the recipient. Unauthorized reproduction, distribution, or disclosure of this report, in whole or in part, in any form or by any means, without the prior written permission of the Company is strictly prohibited.